[1] Feldman C, Shaddock E. Epidemiology of lower respiratory tract infections in adults[J]. Expert Rev Respir Med, 2019, 13(1):63-77. DOI: 10.1080/17476348.2019. 1555040.
[2] Shao J, Hassouna A, Wang Y, et al. Next-generation sequencing as an advanced supplementary tool for the diagnosis of pathogens in lower respiratory tract infections: an observational trial in Xi'an, China[J]. Biomed Rep, 2022, 16(2):14. DOI: 10.3892/br.2021.1497.
[3] Shorr AF, Zilberberg MD, Micek ST, et al. Viruses are prevalent in non-ventilated hospital-acquired pneumonia[J]. Respir Med, 2017, 122:76-80. DOI: 10.1016/j.rmed.2016.11.023.
[4] Marcos PJ, Restrepo MI, González-Barcala FJ, et al. Discordance of physician clinical judgment vs. pneumonia severity index (PSI) score to admit patients with low risk community-acquired pneumonia: a prospective multicenter study[J]. J Thorac Dis, 2017, 9(6):1538-1546. DOI: 10.21037/jtd.2017.05.44.
[5] Brabrand M, Henriksen DP. CURB-65 score is equal to NEWS for identifying mortality risk of pneumonia patients: an observational study[J]. Lung, 2018, 196(3):359-361. DOI: 10.1007/s00408-018-0105-y.
[6] 李明伟,肖慧芳,冯玉龙.凝血功能及机体免疫功能与肺炎严重程度的相关性分析[J].国际医药卫生导报,2023,29(15):2105-2109. DOI:10.3760/cma.j.issn.1007-1245. 2023.15.008.
[7] Guo L, Wei D, Zhang X, et al. Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score[J]. Front Microbiol, 2019, 10:2752. DOI: 10.3389/fmicb.2019.02752.
[8] 卫生部流行性感冒诊断与治疗指南编撰专家组.流行性感冒诊断与治疗指南(2011年版)[J].中华结核和呼吸杂志,2011,34(10):725-734. DOI:10.3760/cma.j.issn.1001- 0939.2011.10.004.
[9] 人禽流感专家组.中国高致病性禽流感A/H5N1病毒感染病例临床管理专家共识(草案)[J].中华结核和呼吸杂志,2009,32(5):329-334. DOI:10.3760/cma.J.issn.1001-0939.2009.05.005.
[10] 中华人民共和国国家卫生健康委员会.新型冠状病毒感染诊疗方案(试行第十版)[J].中华临床感染病杂志,2023,16(1):1-9. DOI:10.3760/cma.j.issn.1674-2397.2023. 01.001.
[11] Qin T, Zhou H, Ren H, et al. Incidence, etiology, and environmental risk factors of community-acquired pneumonia requiring hospitalization in China: a 3-year, prospective, age-stratified, multicenter case-control study[J]. Open Forum Infect Dis, 2021, 8(11):ofab499. DOI: 10.1093/ofid/ofab499.
[12] Zhou F, Wang Y, Liu Y, et al. Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network[J]. Eur Respir J, 2019, 54(2):1802406. DOI: 10.1183/13993003.02406-2018.
[13] Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial[J]. Lancet Glob Health, 2022, 10(1):e42-e51. DOI: 10.1016/S2214-109X(21)00448-4.
[14] Martinez L, Cheng W, Wang X, et al. A risk classification model to predict mortality among laboratory-confirmed avian influenza a H7N9 patients: a population-based observational cohort study[J]. J Infect Dis, 2019, 220(11):1780-1789. DOI: 10.1093/infdis/jiz328.
[15] Li H, Cao B. Pandemic and avian influenza A viruses in humans: epidemiology, virology, clinical characteristics, and treatment strategy[J]. Clin Chest Med, 2017, 38(1):59-70. DOI: 10.1016/j.ccm.2016.11.005.
[16] 赵德余.新冠疫情防控政策工具的选择与比较:从自愿型到强制型[J].中国公共政策评论,2021,18(1):59-78.
[17] Ahmed A, Alderazi SA, Aslam R, et al. Utility of severity assessment tools in COVID-19 pneumonia: a multicentre observational study[J]. Clin Med (Lond), 2022, 22(1):63-70. DOI: 10.7861/clinmed.2020-1107.
[18] Ma B, Gong J, Yang Y, et al. Applicability of MuLBSTA scoring system as diagnostic and prognostic role in early warning of severe COVID-19[J]. Microb Pathog, 2021, 150:104706. DOI: 10.1016/j.micpath.2020.104706.
[19] Preetam M, Anurag A. MuLBSTA score in COVID-19 pneumonia and prediction of 14-day mortality risk: a study in an Indian cohort[J]. J Family Med Prim Care, 2021, 10(1):223-227. DOI: 10.4103/jfmpc.jfmpc_1766_20.
[20] 李勇,林素涵,周月影,等.早期炎症指标与新型冠状病毒肺炎严重程度的相关性研究[J].中华危重病急救医学,2021,33(2):145-149. DOI:10.3760/cma.j.cn121430-20200515- 00387.
[21] 黄凯,俞旭霞,褚金国,等.MuLBSTA评分对新型冠状病毒肺炎重症患者的筛查价值[J].现代实用医学,2020,32(11):1333-1334. DOI:10.3969/j.issn.1671-0800.2020.11.013.
[22] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223):507-513. DOI: 10.1016/S0140-6736(20)30211-7.
[23] 彭佳华,周昌静.MuLBSTA评分联合炎症指标对新型冠状病毒肺炎患者不良结局预测价值[J].右江医学,2022,50(6):407-413. DOI:10.3969/j.issn.1003-1383.2022.06.002.
|